Major bank doubts Novo’s obesity-potential
One of the world’s largest banks has serious doubts about the commercial potential of Victoza following Novo Nordisk’s publication of obesity-studies with the drug. See why?
by Stefan Singh Kailay
The price is too high and efficacy is not high enough compared with existing treatment options, says one of the world’s largest banks, Baclays, in an analysis memo about data from Novo Nordisk’s new obesity-studies with the diabetes drug, Victoza.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
